Omesar Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Omesar Plus is an antihypertensive medication that acts on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure levels in patients with primary hypertension.
• Hypertension with fluid retention: provides additional diuretic effect to reduce excess fluid.
• High‑risk cardiovascular patients: used as part of combination therapy to lower cardiovascular risk.

• Olmesartan medoxomil blocks the binding of angiotensin II to the AT‑1 receptors on vascular smooth‑muscle cells, preventing vasoconstriction. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. Together they produce a synergistic reduction in systemic vascular resistance and blood volume, leading to lower arterial pressure.

Adverse reactions to Omesar Plus may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Severe electrolyte imbalance
• Liver function abnormalities

Before starting Omesar Plus, patients should be evaluated for several safety considerations.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium and sodium levels before and during therapy.
• Pregnancy: avoid use during pregnancy, especially the second and third trimesters.
• Concomitant drugs: review other antihypertensives or potassium‑sparing agents.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omesar Plus can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren: may cause excessive reduction in blood pressure and renal function.
• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect kidney function.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, monitor for hypotension.
• Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.